Singapore Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem. We…
Europe With upcoming EU regulation poised to have a massive impact on ethical regulations around AI in Europe, Bayer Head of Digital Transformation Saskia Steinacker argues that the time is now for pharma executives to start preparing themselves and their teams for the future. “We are in Healthcare. We are…
Global Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight, and makes three bold predictions for the future of the field, especially in emerging countries. As a true believer in the power of technology to transform health,…
Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’. Data is the new oil, but biomedical data – despite its abundance…
Japan Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug discovery process as well as the wider implications for greater use of artificial intelligence in the biotechnology field. The greatest strength of Molcure’s system…
Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19. Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…
China Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges of attaining funding for cutting-edge innovation. Despite being a relatively new company, in 2019, we raised the most money…
Hong Kong Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong. Our research within AI…
Opinion DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of today, including the COVID-19 pandemic. “Standing on the shoulders of giants” is a metaphor, made famous by Isaac Newton,…
Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future. Imagine if we invested billions in epidemiological surveillance…
Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm. AI has the power to enable biopharmaceutical companies to reduce costs and improve…
Global Greg Reh leads Deloitte’s global life sciences sector which includes clients in biopharma, medtech, generics and distribution businesses, as well as non-profit patient advocacy organizations and regulatory agencies. He discusses talent acquisition and retention in global life sciences today, the challenges around data and AI uptake, and the future of…
See our Cookie Privacy Policy Here